Clinical trials: Fibromyalgia (FM)
Fibromyalgia (FM)
EEG Prediction and Clinical Efficacy of tDCS in Fibromyalgia.
The purpose of this randomized controlled trial is to investigate the non-inferiority, and possible superiority, of a high-dose home-based tDCS protocol compared with a conventional home-based protocol, and to assess its…
- Trial name
- FM-TDCS-PREDIC (NCT07583056)
- Testing
- High-dose home-tDCS M1, Conventional home-tDCS, High-dose home-tDCS DLPFC
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Ionclinics & Deionic SL
Fibromyalgia, Myofascial Pain Syndromes
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
The present trial is designed to assess the safety and efficacy of TNX-102 SL 2.8 mg tablets, taken daily at bedtime after 12 weeks of treatment in patients with fibromyalgia.
- Conditions
- Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Nervous System Diseases
- Trial name
- RE-AFFIRM (NCT02829814)
- Testing
- TNX-102 SL Tablet, 2.8 mg
- Where
- 32 sites in United States
- Volunteers
- 51 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Fibromyalgia
A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of…
- Trial name
- RELIEF (NCT04172831)
- Testing
- TNX-102 SL
- Where
- 39 sites in United States
- Volunteers
- 503 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Fibromyalgia
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia
This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of…
- Trial name
- RESILIENT (NCT05273749)
- Testing
- TNX-102 SL Tablet, 5.6 mg
- Where
- 33 sites in United States
- Volunteers
- 457 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Fibromyalgia
A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of…
- Trial name
- RALLY (NCT04508621)
- Testing
- TNX-102 SL
- Where
- 36 sites in United States
- Volunteers
- 514 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Fibromyalgia
Phase 2 Study of TD-9855 to Treat Fibromyalgia
The purpose of this study study is to determine whether TD-9855 is effective in treating patients with fibromyalgia.
- Trial name
- NCT01693692
- Testing
- TD-9855 Group 1, TD-9855 Group 2
- Where
- 34 sites in United States
- Volunteers
- 392 people
- Sponsor
- Theravance Biopharma